Objectives: Previous literature has reported lower morbidity for video-assisted thoracoscopic surgery lobectomy (VL) compared with open lobectomy (OL); however, most comparative studies have been retrospective and have failed to compare well-matched patient groups, therefore allowing selection bias to influence results. Furthermore, oncological adequacy of VL has recently been questioned, particularly with respect to lymphadenectomy. This study aimed to evaluate short- and long-term outcomes of a large cohort of consecutive patients with c-stage I non-small-cell lung cancer (NSCLC) that underwent either VL or OL.

Methods: Consecutive patients with c-stage I NSCLC who underwent lobectomy without preoperative therapy were reviewed. Univariable, multivariable and propensity-matched analyses were performed. VL patients who underwent conversion to OL were analysed within the VL group.

Results: VL was performed in 307 (32%) patients and OL in 656 (68%). Twenty-two (7%) patients converted from VL to OL. Although there were no differences in overall p-stage grouping, there were fewer patients with pT2 tumours in the VL group (39 vs 48%, P = 0.012) and fewer patients with squamous cell histology (26 vs 18%, P = 0.006). These differences resolved after propensity matching. In unmatched and matched analyses, VL was associated with less overall morbidity, less pulmonary morbidity, fewer atrial arrhythmias, shorter chest tube duration and shorter hospital stay than patients who had OL. Thirty-day in-hospital mortality was 0.3 and 1.4%, for VL and OL groups, respectively (P = NS). In unmatched analysis (log rank), 5-year survival favoured VL (78 vs 68%, P = 0.007); however, after propensity matching there was only a trend towards improved survival with VL (78 vs 73%, P = 0.071). Multivariable Cox regression analysis revealed VL (hazard ratio (HR) 0.64, 95% confidence interval (CI) 0.46-0.92), male sex (HR 1.43, 95% CI 1.10-1.86), Zubrod performance status (HR 3.42, 95% CI 1.26-9.29) and increasing age (HR 1.04, 95% CI 1.03-1.06) to be independent predictors of survival.

Conclusions: Patients with clinical Stage I NSCLC undergoing VL have less perioperative morbidity compared with matched OL controls. Regional lymphadenectomy, nodal upstaging, overall and disease-free survival were similar between VL and OL groups. In experienced centres, VL is an acceptable operation for patients with c-stage I NSCLC.

Download full-text PDF

Source
http://dx.doi.org/10.1093/ejcts/ezu036DOI Listing

Publication Analysis

Top Keywords

patients c-stage
12
patients
10
compared open
8
open lobectomy
8
clinical stage
8
non-small-cell lung
8
lung cancer
8
consecutive patients
8
nsclc underwent
8
c-stage nsclc
8

Similar Publications

Introduction And Hypothesis: The aim of the study was to compare clinical outcomes when using robotic-assisted sacral hysterocolpopexy (RASC) and vaginal surgery using the Uphold™ Vaginal Support System mesh for pelvic organ prolapse repair.

Methods: This was a nonrandomized, prospective, multicenter study in which 72 women underwent RASC, and 73 Uphold™ surgery, for apical prolapse (POP-Q C ≥ stage II). Anatomical outcomes were assessed using the Pelvic Organ Prolapse Quantification (POP-Q) system.

View Article and Find Full Text PDF
Article Synopsis
  • The study explored new imaging criteria using maximum standardized uptake value (SUVmax) to predict less-invasive lung adenocarcinoma stages IA2-IA3.
  • A retrospective analysis of 364 patients with tumors under 3 cm was conducted, with results showing varying sensitivity and specificity based on tumor characteristics and size when using an SUVmax cutoff of 2.2.
  • Ultimately, establishing the SUVmax cutoff could help identify pathologically less-invasive cancers in the specified stages of solid predominant lung adenocarcinoma.
View Article and Find Full Text PDF
Article Synopsis
  • * A study of 402 Brazilian CD patients analyzed genetic polymorphisms in genes related to CD and its progression to determine associations with CARD severity, using logistic regression to adjust for factors like age and treatment.
  • * Although some genetic variants suggested potential links to CARD severity, no strong associations were confirmed after adjusting for multiple comparisons, while a specific haplotype showed protective effects against severe CARD progression.
View Article and Find Full Text PDF

Efficacy of atezolizumab-bevacizumab combination therapy early after recurrence of hepatocellular carcinoma following resection or ablation with a curative intent.

Ann Gastroenterol

October 2024

Academic Department of Internal Medicine - Hepatogastroenterology Unit, "Agioi Anargyroi" General and Oncology Hospital of Kifisia, National and Kapodistrian University of Athens (Spyridon Pantzios, Antonia Syriha, Ioanna Stathopoulou, Sofia Rellou, Georgia Barla, Ioannis Elefsiniotis).

Background: The pattern of hepatocellular carcinoma (HCC) recurrence after resection/ablation is intrahepatic and/or systemic. The efficacy of atezolizumab-bevacizumab treatment as early therapy after recurrence has not been extensively evaluated.

Methods: We evaluated 32 patients (group A) with early HCC recurrence after resection/ablation and 24 patients (group B) initially diagnosed as Barcelona Clinic Liver Cancer (BCLC)-C, all treated with atezolizumab-bevacizumab.

View Article and Find Full Text PDF
Article Synopsis
  • - The study compared long-term survival outcomes of robotic-assisted thoracic surgery (RATS) and video-assisted thoracic surgery (VATS) for patients with stage Ⅰ non-small-cell lung cancer (NSCLC) between 2015 and 2017.
  • - After analyzing data from 518 patients, it was found that RATS had shorter operation times and more lymph nodes removed compared to VATS, but overall survival rates were similar between the two techniques.
  • - The analysis indicated that the number of lymph nodes dissected is linked to better overall survival, suggesting that this factor is more crucial than the choice of surgical method.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!